CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Q3 2026 earnings due after market close today is the dominant near-term catalyst, amplified by a fresh BTIG price target raise to $81 and positive ASN clinical data; sentiment skews positive but binary on results.
CareDx reports Q3 2026 financial results after market close on October 29, 2026, with a call at 4:30 p.m. ET. Given Q2's 52% revenue growth and raised full-year outlook, plus BTIG's expectation of a ~5% revenue beat and higher 2026 guidance, the print and guidance are the primary binary driver of near-term price action.
CareDx Press ReleaseBTIG lifted its price target to $81 from $74 while keeping a Buy rating, citing expected material upside to 2027 revenue estimates and a likely ~5% revenue beat in upcoming results. The upgrade reinforces positive momentum ahead of earnings and implies ~17% upside from the $69.10 level cited.
Investing.comNew KOAR registry data linked elevated AlloSure Kidney levels to nearly 3-fold higher risk of adverse graft outcomes, and an independent randomized trial showed 49% fewer biopsies with dd-cfDNA monitoring while maintaining similar outcomes. The supportive evidence strengthens the clinical adoption narrative for AlloSure and supports sentiment into the earnings print.
CareDx Press ReleaseThe finalized Medicare Local Coverage Determination affirming coverage for AlloSure Kidney, AlloMap, AlloSure Heart and AlloSure Lung took effect August 30, 2026, removing a major reimbursement overhang though hard-coding test-frequency limits. Investors will watch management commentary on utilization against these limits in today's results, making it a secondary but relevant driver.
RTTNews